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Key points 
FLAIR* in a clinical setting allows visualization of veins in white matter lesions. 
Significant proportions of MS lesions demonstrate a vein in lesion on MRI. 
Microangiopathic lesions demonstrate a lower proportion of intralesional veins than MS 
lesions. 
Intralesional vein-based criteria appear more sensitive for MS than McDonald MRI criteria. 
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Abstract 
Objective: To explore the potential of a post-processing technique combining FLAIR 
and T2* (FLAIR*) to distinguish between lesions caused by multiple sclerosis (MS) 
from cerebral small vessel disease (SVD) in a clinical setting. 
 
Methods: FLAIR and T2* datasets of the head acquired at 3T of 25 people with 
relapsing MS (pwRMS) and 10 with cerebral small vessel disease (pwSVD) were used. 
After post-processing, FLAIR* maps were used to determine the proportion of white 
matter lesions (WML) showing the ‘vein in lesion’ sign (VIL), a characteristic 
histopathological feature of MS plaques.  Sensitivity and specificity of a diagnosis of 
MS were examined on the basis of >45% VIL+ and >60% VIL+ WML, and compared 
with current dissemination in space (DIS) MRI criteria. 
 
Results: All pwRMS had >45% VIL+ WML (range 58-100%) whilst in pwSVD the 
proportion of VIL+ WML was significantly lower (range 0-64%; mean 32 ± 20%). 
Sensitivity based on the rule of >45% VIL+ was 100% and specificity 80% whilst using 
the >60% VIL+ as criterion sensitivity was 96% and specificity 90%. DIS criteria had 
96% sensitivity and 40% specificity. 
 
Conclusion: FLAIR* enables VIL+ WML detection in a clinical setting, facilitating 
differentiation of MS from SVD based on brain MRI.  
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INTRODUCTION 
No noninvasive test result is fully specific for the diagnosis of multiple sclerosis (MS), 
one of the most common conditions causing chronic neurological disability. The 
current diagnostic criteria for MS (‘McDonald’ criteria) are based on clinical and 
paraclinical evidence, including magnetic resonance imaging (MRI), of dissemination 
in time (DIT) and space (DIS) of lesions suggestive of inflammatory demyelination. 
These criteria also rely on the exclusion of alternative conditions that would better 
explain a patient’s symptoms, signs, and results of investigations [1]. The stipulation 
of “no better explanation” underpins the character of MS as a diagnosis of exclusion. 
 
MRI of the brain and spinal cord is the single most important investigation in the 
diagnostic work-up of people suspected of having MS, and serves both the 
diagnostic criteria laid down by the International Panel [1] and the exclusion of 
differential diagnoses. However, lesions suggestive of demyelination detected on 
conventional T2-weighted MRI may in fact have a different pathological substrate, 
such as cerebral small vessel disease (SVD), migraine, or infections [2]. The 
probability of one of these alternative diagnoses may depend, for example, on age, 
vascular risk factors, or genetic background. Strict adherence to the current criteria 
can therefore delay the definitive diagnosis of MS and, as a result, disease modifying 
treatment (DMT). Given the evidence that treatment of people with MS, particularly 
those with a relapsing course (pwRMS), is most effective when started early, such 
delay may be clinically important [3-5]. 
 
Another limitation of current MRI techniques is apparent in people with MS who also 
have risk factors for SVD. Comorbidity may compromise correct allocation of new 
lesions to their cause [6], and such uncertainty may directly impact on treatment 
decisions [7, 8]. 
 
In order to further improve MRI as a tool to support a diagnosis of MS, one of its 
characteristic histological features has recently been revisited: the vein about which 
MS lesions almost invariably evolve [9,10]. This perivenous morphology of MS 
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lesions appears to have become accessible in vivo using MRI techniques susceptible 
to iron in deoxygenated haemoglobin, such as susceptibility or T2*-weighted imaging 
[11]. 
 
In a study using T2*-weighted imaging at 7T, the detection of “veins in lesions” (VIL) 
suggested VIL may be useful as a diagnostic marker for MS [12]. A further study by 
the same group suggested a proportion of 40% or more VIL positive (VIL+) white 
matter lesions (WML) distinguished people with MS (pwMS) from people with WML 
of a different aetiology with 100% positive and negative predictive values [13].  
 
Whilst 7T MRI currently provides the best platform in terms of signal-to-noise and 
resolution to detect WML and cerebral veins alike, 7T scanners are not widely 
available, particularly in clinical settings, and a substantial number of WML and 
cerebral veins can also be visualized at 3T [14]. At 3T, a proportion of 45% VIL+ WML 
has been shown to correctly categorize patients as having MS or SVD lesions [15]. 
 
In the study reported here, T2*-weighted 3D echo-planar-imaging (3D EPI), to detect 
VIL, and T2-weighted fluid attenuated inversion recovery (FLAIR) sequences, to 
detect WML, were acquired at 3T and combined to generate FLAIR* images, first 
described by Sati and co-workers [16]. 
 
Using datasets acquired in a routine clinical setting we explored the sensitivity and 
specificity of a set of criteria based on FLAIR* for comparison with the revised 
International Panel MRI criteria currently used to support a diagnosis of MS. We 
further compared our results to a group of patients with WML and a clinical profile 
consistent with SVD to determine whether the proportion of VIL+ WML could be 
useful in differentiating MS from SVD. 
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MATERIALS & METHODS 
Subjects 
This study was approved by the National Research Ethics Committee North West – 
Haydock (15/NW/0065) and undertaken at a single centre, The Royal London 
Hospital (RLH), Barts Health NHS Trust, London, UK. Datasets were used of patients 
who had undergone MRI as part of routine care. Written informed consent was 
obtained prior to any study procedure. Principal sources of referrals were the 
Neurology & Neuroinflammation services of the RLH, with additional referrals 
facilitated by the National Institute of Health Research (NIHR), North Thames Clinical 
Research Network. For inclusion in the study MRI brain studies had to show at least 
one white matter lesion. Datasets of pwRMS were included if the diagnosis was 
confirmed according to the most recent International Panel criteria [1]. Datasets of 
people with SVD (pwSVD) were included if they (i) did not have a clinical diagnosis of 
MS (and were not suspected of having MS) and (ii) had at least 2/6 risk factors for 
SVD (diabetes, high blood pressure, smoking, hypercholesterolaemia, ischaemic 
heart disease, peripheral vascular disease [17]). Datasets of patients with any 
additional CNS pathology were excluded. 
 
Data Acquisition 
 
All images were acquired on a Philips Achieva 3T TX system (Philips Healthcare, Best, 
The Netherlands) based at St Barts Hospital of Barts Health NHS Trust using either a 
16-element neurovascular coil or an 8-element head coil. The protocol included a 
T2*-weighted 3D segmented EPI sequence (TE 29ms, TR 53ms, flip angle 10, EPI 
factor 15, field of view 240240180mm3, 0.550.550.55mm3 resolution, SENSE 
acceleration 22, total acquisition time 3min50s) [18] and a 3D FLAIR sequence 
(VISTA protocol, TE 372ms, TR 4800ms, TI 1600ms, field of view 240240180mm3, 
111mm3 resolution, SENSE acceleration 22.6, total acquisition time 6min) after 
injection of 10ml of 0.5mmol/ml gadoteric acid contrast agent. Contrast was injected 
manually  right before the T2* sequence was acquired. FLAIR was acquired 13 
minutes post contrast administration. The scanner manufacturer provided both 
sequences. 3D T1 (fast field echo; before and after administration of gadolinium) and 
Page 6 
 
Page 6 of 16 
3D T2 (turbo spin echo) sequences were also obtained in order to assess lesions 
according to the McDonald criteria. Due to our local scanning protocols, please note 
that these scanning parameters differ slightly from those described by Sati et al. 
[16]; a standard contrast dose with manual injection was used instead of a weight-
adjusted contrast dose via power injector, and thus the delay to the FLAIR sequence 
was longer. 
 
Image Processing 
 
FLAIR* images were constructed using the FLAIR and T2* datasets using MIPAV 
(mipav.cit.nih.gov) and JIST (www.nitrc.org/projects/jist/) image processing 
software. Post-processing was conducted using a processing pipeline as described 
previously [16]. All images were first reformatted to the axial orientation without 
interpolation. To correct for motion between acquisitions, the FLAIR dataset was co-
registered to the 3D EPI sequence using a rigid registration with six degrees of 
freedom, normalised mutual information as the cost function, and windowed sinc 
interpolation. The registered FLAIR images were then interpolated to the same 
spatial resolution and multiplied to the 3D EPI sequence to obtain the FLAIR* images 
(fig. 1).  
 
Data Analysis 
MRI data were assessed by a neuroradiology fellow (RJPS) and a radiology trainee 
with specific neuroradiology training (TC), supervised by a senior consultant 
neuroradiologist (JE). Both assessors were blinded to clinical information. WML were 
defined as discrete areas of high signal intensity on FLAIR* images with a minimum 
diameter of 3mm. Their number, location, and whether or not they were VIL+ 
(defined as containing a hypo-intense line or dot on axial FLAIR*) were recorded (fig. 
2). Inter-observer agreement of the presence/absence of VIL+ WML was assessed on 
a lesion level using Cohen’sκcoefficient calculated using Microsoft Excel. Additional 
statistical analysis was performed using StatPlus. 
 
Only WML identified by both observers were included in the analysis. Where there 
was disagreement between observers about the presence of VIL, images were jointly 
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re-evaluated and a consensus reached. The proportion of VIL+ WML was then 
determined for each patient. A proportion of 45% or more of VIL+ WML was 
considered diagnostic for MS (the ‘VIL45’ criterion)[15]. The proportion in the MS 
and SVD cohorts was compared using the Mann Whitney test. We also assessed the 
value of a higher threshold (a proportion of 60% or more; ‘VIL60’ criterion) to 
determine whether this would impact on sensitivity and specificity. 
 
Recent evidence suggests that a thorough assessment of only a limited number of 
‘morphologically characteristic lesions’ (MCLs, i.e. VIL+ WML) can be used [15] as an 
alternative to calculating the relative proportion of VIL+ WML.  We applied a slightly 
simplified version of these criteria (‘rule of six criteria’) to our dataset as follows: 
1. If there were six or more VIL+ WML, a diagnosis of MS was assigned. 
2. If there were fewer than six VIL+ WML, however VIL+ WML outnumbered VIL- 
WML, a diagnosis of MS was assigned. 
3. If neither of these conditions was met, MRI was deemed not confirmatory for 
a diagnosis of MS. 
 
Finally, datasets of each participant were inspected to determine whether they fulfill 
the standard DIS and DIT criteria. DIS was considered fulfilled if lesions were 
identified on T2 weighted scans in two or more areas characteristic for MS. DIT was 
considered fulfilled if both enhancing and non-enhancing WML were present in 
parallel on the 3D T1 post-gadolinium sequence.[1].  
 
Sensitivity, specificity and accuracy for the diagnosis of MS were calculated for three 
VIL-based criteria (VIL45, VIL60 and ‘rule of six’) and two McDonald based criteria 
(DIS alone, and DIS & DIT). McNemar test was used to compare the number of 
pwRMS and pwSVD who were VIL45+ and VIL60 + with the number of pwRMS who 
fulfilled the DIS, and DIS & DIT (McDonald 2010 MRI) criteria. 
 
 
RESULTS 
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Datasets of 25 pwRMS (14 men and 11 women; age 41 ± 11 years; disease duration 6 
± 5 years) and 10 pwSVD (4 men and 6 women; age 59 ± 9 years) were used. pwSVD 
were older (p<0.01). 14/25 of pwRMS were on various DMT at the time of scanning. 
 
The inter-observer agreement for determining whether a given WML was VIL+, 
calculated on a lesion by lesion basis, was moderate (κ = 0.70)[19]. 
 
In pwRMS, a total of 338 WML were identified (range 5-31; mean 14 ± 7). Of these, 
291 WML (86%) were VIL+.  At least 58% VIL+ WML were detected in each pwRMS 
(range 58-100%; mean 88 ± 12%). All pwRMS met the ‘rule of six’ criteria for MS. 
 
Twenty-four pwRMS (96%) fulfilled the McDonald DIS criterion, whilst three (12%) 
fulfilled both DIS & DIT.  
 
There was significant difference in the mean proportion of VIL+ WML between 
pwRMS on DMT and patients that were not (On DMT 83%, not on DMT 94%, p = 
0.013). 
 
In pwSVD, a total of 136 WML was identified (range 0-33; mean 13 ± 9). Of these, 54 
(40%) were VIL+. The mean proportion of VIL+ WML was significantly lower (range 0-
64%; mean 32 ± 20%) than in pwRMS (p<0.0001) (fig. 3). 3/10 pwSVD met the ‘rule 
of six’ criteria for MS. Six/10 pwSVD fulfilled the McDonald 2010 DIS criteria; none 
fulfilled both DIS & DIT. 
 
The VIL45 criterion had a diagnostic sensitivity of 100% and a specificity of 80%. The 
respective figures for VIL60 were 96% and 90%. The ‘rule of six’ criterion had a 
sensitivity of 100% and a specificity of 70%. 
 
The McDonald 2010 DIS criterion had a sensitivity of 96% and a specificity of 40%. 
(table 1). 
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DISCUSSION 
 
The McDonald MRI criteria are based on a DIS component, which depends on the 
morphology and distribution pattern of WML, and a DIT component inferred from 
either (i) the presence in parallel of Gadolinium-enhancing (Gd+) and non-enhancing 
(Gd-) WML at baseline, or (ii) new WML, be they Gd+ or Gd-, on follow-up MRI. 
Although the most recent edition of these criteria has improved and simplified the 
interpretation of MRI scans to support a diagnosis of MS [1], their applicability in 
clinical practice remains imperfect [20, 21]. 
 
As an alternative to, or perhaps to complement, the pattern-based approach used in 
the McDonald MRI criteria, the detection and interpretation of VIL+ WML in vivo 
benefits from the routine availability of MRI techniques susceptible to deoxygenated 
blood [22], which appears to enable the visualisation of a histological hallmark of MS 
WML described for over 160 years, the perivenular morphology of WML [23]. 
Although we are not aware of any correlative post mortem MRI/pathology studies 
the topography of hypo-intensity within WML and the presence of 
deoxyhaemoglobin within veins (which increase susceptibility effects) suggest VIL+ 
WML most likely represent lesions that have emerged around veins. 
 
Using manufacturer-provided sequences acquired at a routine clinical field strength, 
FLAIR* detected VIL in over 60% of WML in all but one pwRMS included in this study. 
At a single time point, and using either the threshold of 45% as proposed in earlier 
studies using 7T [12] and 3T [15] MRI, or a threshold of 60% the presence of VIL+ 
WML corroborated the diagnosis of MS in all (bar one in the VIL60 analysis) 
participants studied as did the ‘rule of six, though with a lower specificity.  
 
The McDonald DIS criterion was as sensitive as the VIL based indices employed, 
however its specificity was significantly lower (40% versus 70-90%).  Whilst 40% 
appears particularly low, it has previously been shown that DIT information is a key 
contributor towards specificity in the McDonald MRI criteria [24]. Our study supports 
Page 10 
 
Page 10 of 16 
previous work in demonstrating a significantly higher proportion of VIL+ WMLs in 
pwMS compared to pwSVD [12].  
 
However, given that two pwSVD were VIL45+, and one VIL60+, the thresholds used 
were not absolute discriminators. The reason for this may be that veins can 
incidentally cross SVD lesions thereby giving the wrong impression of a “classic” VIL+ 
WML. Moreover, the lack of post mortem evidence leaves some uncertainty what 
exact proportion of hypo-intensities in WML indeed represent veins. On the other 
hand, VIL+ WML in pwMS may be missed due to their small size/diameter. To 
maximize diagnostic value it may therefore be necessary to combine criteria largely 
based on lesion morphology with criteria based on distribution pattern and location. 
A more stringent definition of what constitutes an MS related VIL may also likely be 
required [10].  
 
The difference in the mean proportion of VIL+ WML supports the growing body of 
evidence suggesting this radiological sign is a useful additional discriminator, in 
contrast to previous research demonstrating no added benefit [25]. Susceptibility 
weighted imaging to demonstrate VIL+ WML also suggested high sensitivity and 
specificity for the diagnosis of MS [26,27]. However, inspection of the FLAIR* maps 
acquired in our and previous studies [16,28] suggests there are advantages in 
combining high isotropic resolution T2*-weighted MRI with a well-established 
technique for WML detection: recognizing VIL+ WML on FLAIR* appears more 
straightforward than on T2* alone (fig. 4). This is in line with another recent study 
demonstrating that using FLAIR and FLAIR* as part of a global assessment of 
whether >40% WMLs contain a vein improves diagnostic accuracy for MS without 
the need to assess every single lesion [28]. 
 
Limitations 
Though image reviewers were often unaware of the diagnosis, systematic blinding 
was not undertaken. Moreover, most pwRMS were on DMT when MRI datasets were 
acquired, compromising the potential to reveal Gd+ WML and likely explaining the 
particularly small number (3) of pwRMS in our study meeting DIT criteria at a single 
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time point [24]. A limitation inherent in the method is that identification of VIL+ 
WML remains to some extent subjective; although agreement in our study between 
raters was moderate (κ = 0.70), specific training and reading criteria may be required 
to introduce the VIL sign as a standard in clinical practice. 
 
The acquisition protocol of our study was slightly different from previous studies 
using similar methodology [16,28]. In particular, manual administration of the 
contrast medium followed by the T2* sequence, and a different dosing regime 
(standard instead of weight adjusted dose) may have altered the vein vs lesion 
contrast with possible impact on the VIL45 and VIL60 indices and inter-rater 
agreement. 
 
Finally, pwSVD were older than those in the MS group, thus providing an imperfect 
match for the pwRMS cohort. However, higher numbers of WML are to be expected 
with age, and as such older people should represent a more challenging comparator 
group to test the VIL criteria. Future studies should compare FLAIR* with McDonald 
criteria in a larger cohort of people where MS is the suspected diagnosis, i.e. people 
with a first manifestation of symptoms and/or signs suggestive of demyelination, 
and acquire FLAIR* at the time of presentation and after defined subsequent 
intervals. FLAIR* has already shown promise in differentiating between MS and 
migraine, for example [29]. 
 
CONCLUSION 
In a clinical setting, and using standard manufacturer-supplied sequences, FLAIR* at 
3T reliably enabled in vivo detection of VIL+ WML, which resemble a characteristic 
histological feature of MS. All pwRMS were VIL45+, underpinning previous data 
acquired in a research setting. The mean proportion of VIL+ WML was significantly 
higher in pwRMS compared to pwSVD.  
 
Our data suggests that using either VIL45 or VIL60 is as sensitive, and potentially 
more specific, for the diagnosis of MS than current McDonald 2010 MRI criteria. 
FLAIR* may thus support the development of more accurate and easy to use MRI 
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criteria for a diagnosis of MS. In line with the recent first consensus statement on the 
evaluation of central veins in WML [10] further prospective and comparative studies 
are required to confirm the diagnostic value of VIL, and the techniques used to 
visualize these and other features of MS. 
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Figure Legends: 
 
Figure 1. Construction of FLAIR* images. a: FLAIR, axial slice. b: T2*, axial slice. c: 
Combined images create FLAIR*, axial slice. White arrow indicates intralesional vein. 
 
Figure 2. VIL+ lesions on FLAIR* in a patient with MS. a: Multiple periventricular VIL+ 
lesions. b: Subcortical VIL+ lesion. 
 
Figure 3. Proportion of VIL+ lesions in MS and SVD cohorts. 
 
Figure 4. T2* versus FLAIR*. a-c: Partial T2* slices from three patients with MS: a 
axial, b axial, and c coronal. White circle indicates vein, although lesions not clearly 
identified. d-f: Corresponding partial FLAIR* slices at same level. White circle 
indicates white matter lesion around the same vein.  
 
Table 1. Table demonstrates sensitivity, specificity and accuracy calculations (95% 
confidence intervals given underneath each value) using the McDonald MRI DIS 
criterion, the VIL45 and VIL60 criteria and the ‘rule of six’ criteria.  
 
 
 
 
